

OSTEOPORE CREATES ADVISORY PANEL WITH DISTINGUISHED INDUSTRY LEADERS

27 February 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce that Mr Greg Rudd has joined its newly setup Advisory Panel. He joins Mr David Yeow, Dr James Tan, Dr Samintharaj Kumar, Dr GK Ananda, Dr Michael Wagels and Ms Joy Song as other distinguished members.

Osteopore’s Advisory Panel will provide a valuable source of guidance and support for the organisation by tapping into the relevant expertise, networks and channels that its panel members can offer. The panel will play a pivotal role in enhancing Osteopore’s footprint globally, advancing scientific research and support its commercialisation efforts. The panel includes members who have expertise in areas such as market access, R&D, commercialisation, craniofacial, orthopaedic, aesthetic, dental, and oral-maxillofacial surgery.

Executive Chairman, Mark Leong said:

“We are thrilled and honoured to have these outstanding individuals join our advisory panel, and are confident that their individual expertise and insights will help us grow our global footprint. Osteopore’s bioresorbable scaffold technology is attracting the interest of personalities with international standing, which is a testament to the impact our innovative solutions can have in the healthcare industry. We believe that having access to their collective wisdom and experience will allow us to further advance our mission of improving patient outcomes and driving positive outcomes for shareholders.”

Distinguished members of Osteopore’s Advisory Panel include:



MR GREG RUDD

Mr Greg Rudd is a well-known Australian lobbyist and business consultant. With his extensive experience in government relations, entrepreneurship, and cyber security, Mr Rudd brings a wealth of knowledge and expertise to the Osteopore team. Recently, Mr Rudd was given a tour of Osteopore’s manufacturing facility in Singapore, where he was briefed on how the Company’s technology has proven to be a more effective treatment than traditional bone grafts and permanent implants.

As the former Chief-of-Staff to a Federal Minister and the founder of his own Government Relations Consultancy, Mr Rudd has a proven track record of providing strategic advice and guidance across various industry sectors. In addition to his experience in business consulting, he has also served as a director and chairman of several start-up companies.



DR MICHAEL WAGELS

Dr Michael Wagels is a Staff Specialist Plastic and Reconstructive surgeon at the Princess Alexandra Hospital. Dr Wagels established the first multi-specialty point of care manufacturing facility in Brisbane at the Australian Centre for Complex Integrated Surgical Solutions on the Princess Alexandra Hospital campus. He has recently been appointed the Clinical Director of the Herston Biofabrication Institute, a large scale point of care manufacturing enterprise with a multi-million dollar research programme.

Dr Wagels is a staunch believer in clinical and research collaborations for the benefit of patients and sees that there is no better example of this than in surgery and engineering. He is proud of his existing collaborations and what these have achieved, most notably the world's first long segment load bearing long bone reconstruction in a human using regenerative matching axial vascularization of an absorbable 3D printed scaffold. These principles have recently been translated to first in human trials of bioresorbable implants for cranioplasty, mandible reconstruction and camouflage correction of pectus excavatum with translatability to breast reconstruction.



MR DAVID YEOW

Mr David Yeow is recognised as a leading practitioner in financial services regulations in the legal advisory. He is currently an independent director of UOB Kay Hian Holdings Ltd (listed on SGX) and Nicheliving Capital Ltd. He was an advocate and solicitor of the Supreme Court of Singapore, senior partner (since 1999) and also ex officio executive committee member of Rajah & Tann LLP. He also previously served as independent director of Noble Group Ltd and Bund Center Investment Ltd (both listed on SGX).



MS JOY SONG

Ms Joy Song is a co-founder of Cellheal Therapeutics, a clinical stage company developing personalised cell and targeted therapies for oncology and regeneration. Ms Song is a highly accomplished and awarded executive with multidisciplinary skills in broad Business Finance/Economics and Research. She manages a team in Australia and China and has been instrumental in strategy development, licensing, initiating and managing pre-clinical studies /clinical trials, fundraising and business development.

Previously, Ms Song had a distinguished career as an investment banker specialising in the life sciences sector, where she consistently works with leading brokers in primary and secondary offerings, corporate advisory and M&A assignments. In particular, she leveraged her combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors in Australia and China.

Ms Song holds a Bachelor of Commerce with an Honours Degree in Economics and Finance (breath in Law) from the University of Melbourne. She has been a collaborator on various economics, econometrics, finance and law research projects.



DR JAMES TAN

Dr James Tan is a highly experienced Sports Surgeon and industry Key Opinion Leader (Johnson & Johnson) with 20 years of experience. As a founding member of the Singapore Shoulder & Elbow Society and a member of the Asian Shoulder & Elbow Group, he has treated athletes from Singapore National Senior and Youth Teams and professional footballers from the Young Lions and Singapore Premier League clubs.

Dr Tan has a strong track record in healthcare administration and headed the Khoo Teck Puat Hospital (KTPH) Department of Orthopaedic Surgery & Sports Medicine Centre from 2016 to 2020. He was the clinician lead for Musculoskeletal Disease, at the Centre for Medical Technologies and Innovations (CMTi), National Healthcare Group (NHG).



DR SAMINTHARAJ KUMAR

Dr Samintharaj Kumar is dual-qualified in Medicine and Dentistry and is the CEO and Founder of Nuffield Holdings. He provides the full clinical spectrum of Dental Implantology and is both the MALO DENTAL Director for Singapore and also the ZAGA Centre Director for Singapore.

Dr Kumar has published papers in internationally peer reviewed journals. He was an internal examiner for the Overseas Registration Examination (ORE) and previously a mentor for the Society of the Advancement of Anaesthesia in Dentistry (SAAD). Postgraduate Examinations that he passed through formal examination include the MFDS RCS, Royal College of Surgeons in England, MFD RCSI, Royal College of Surgeons of Ireland, MRCS Royal College of Surgeons of England and the MBA, Sir John Cass Business School, London. In 2019 he was conferred as a Fellow to the International College of Dentists. In 2020, he was elected as Council Member to the Singapore Dental Association.



DR GK ANANDA

Dr GK Ananda has almost two decades of experience in Oral and Maxillofacial surgery. Prior to starting his private practice, he served as the Head of Department for Enche' Besar Hajjah Khalsom Hospital, Johor, Malaysia.

Dr GK has extensive experience in facial reconstruction. Some of his specialties include repair of Cranio-Maxillofacial (facial) Trauma, secondary facial reconstruction, orthognathic (jaw) surgery, dental implantology, and facial aesthetic work.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.